PepGen (PEPG) Stock Forecast, Price Target & Predictions
PEPG Stock Forecast
PepGen stock forecast is as follows: an average price target of $29.50 (represents a 334.46% upside from PEPG’s last price of $6.79) and a rating consensus of 'Buy', based on 2 wall street analysts offering a 1-year stock forecast.
PEPG Price Target
The average price target for PepGen (PEPG) is $29.50 based on 1-year price targets from 2 Wall Street analysts in the past 3 months, with a price target range of $33.00 to $26.00. This represents a potential 334.46% upside from PEPG's last price of $6.79.
PEPG Analyst Ratings
According to 2 Wall Street analysts, PepGen's rating consensus is 'Buy'. The analyst rating breakdown for PEPG stock is 0 'Strong Buy' (0.00%), 2 'Buy' (100.00%), 0 'Hold' (0.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).
PepGen Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Dec 21, 2022 | - | H.C. Wainwright | $26.00 | $14.51 | 79.19% | 282.92% |
| Nov 10, 2022 | - | Leerink Partners | $33.00 | $12.50 | 164.00% | 386.01% |
The latest PepGen stock forecast, released on Dec 21, 2022 by H.C. Wainwright company, set a price target of $26.00, which represents a 79.19% increase from the stock price at the time of the forecast ($14.51), and a 282.92% increase from PEPG last price ($6.79).
PepGen Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | - | - | - |
| Avg Price Target | - | - | - |
| Last Closing Price | $6.79 | $6.79 | $6.79 |
| Upside/Downside | -100.00% | -100.00% | -100.00% |
In the current month, the average price target of PepGen stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to PepGen's last price of $6.79. This month's average price target is down NaN% compared to last quarter, and down NaN% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Nov 10, 2022 | SVB Leerink | Outperform | Outperform | Hold |
| May 31, 2022 | Bank of America Securities | - | Buy | Initialise |
PepGen's last stock rating was published by SVB Leerink on Nov 10, 2022. The company gave PEPG a "Outperform" rating, the same as its previous rate.
PepGen Financial Forecast
PepGen Revenue Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | |
|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - |
| Avg Forecast | - | - | - | - | - | - | - |
| High Forecast | - | - | - | - | - | - | - |
| Low Forecast | - | - | - | - | - | - | - |
| # Analysts | - | - | - | - | - | - | - |
| Surprise % | - | - | - | - | - | - | - |
PepGen's average Quarter revenue forecast for undefined based on undefined analysts is $NaN, with a low forecast of $NaN, and a high forecast of $NaN. PEPG's average Quarter revenue forecast represents a NaN% decrease compared to the company's last Quarter revenue of $NaN (undefined).
PepGen EBITDA Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | |
|---|---|---|---|---|---|---|---|
| # Analysts | - | - | - | - | - | - | - |
| EBITDA | - | - | - | - | - | - | - |
| Avg Forecast | - | - | - | - | - | - | - |
| High Forecast | - | - | - | - | - | - | - |
| Low Forecast | - | - | - | - | - | - | - |
| Surprise % | - | - | - | - | - | - | - |
undefined analysts predict PEPG's average Quarter EBITDA for undefined to be $NaN, with a high of $NaN and a low of $NaN. This is NaN% lower than PepGen's previous annual EBITDA (undefined) of $NaN.
PepGen Net Income Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | |
|---|---|---|---|---|---|---|---|
| # Analysts | - | - | - | - | - | - | - |
| Net Income | - | - | - | - | - | - | - |
| Avg Forecast | $-26.48M | $-26.21M | $-27.83M | $-27.55M | $-27.99M | $-28.20M | $-23.44M |
| High Forecast | $-26.48M | $-26.21M | $-27.83M | $-27.55M | $-27.99M | $-20.74M | $-23.44M |
| Low Forecast | $-26.48M | $-26.21M | $-27.83M | $-27.55M | $-27.99M | $-31.76M | $-23.44M |
| Surprise % | - | - | - | - | - | - | - |
PepGen's average Quarter net income forecast for undefined is $NaN, with a range of $NaN to $NaN. PEPG's average Quarter net income forecast represents a NaN% decrease compared to the company's last Quarter net income of $NaN (undefined).
PepGen SG&A Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | |
|---|---|---|---|---|---|---|---|
| # Analysts | - | - | - | - | - | - | - |
| SG&A | - | - | - | - | - | - | - |
| Avg Forecast | - | - | - | - | - | - | - |
| High Forecast | - | - | - | - | - | - | - |
| Low Forecast | - | - | - | - | - | - | - |
| Surprise % | - | - | - | - | - | - | - |
PepGen's average Quarter SG&A projection for undefined is $NaN, based on undefined Wall Street analysts, with a range of $NaN to $NaN. The forecast indicates a NaN% fall compared to PEPG last annual SG&A of $NaN (undefined).
PepGen EPS Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | |
|---|---|---|---|---|---|---|---|
| # Analysts | - | - | - | - | - | - | - |
| EPS | - | - | - | - | - | - | - |
| Avg Forecast | $-0.82 | $-0.81 | $-0.86 | $-0.85 | $-0.86 | $-0.87 | $-0.72 |
| High Forecast | $-0.82 | $-0.81 | $-0.86 | $-0.85 | $-0.86 | $-0.64 | $-0.72 |
| Low Forecast | $-0.82 | $-0.81 | $-0.86 | $-0.85 | $-0.86 | $-0.98 | $-0.72 |
| Surprise % | - | - | - | - | - | - | - |
According to undefined Wall Street analysts, PepGen's projected average Quarter EPS for undefined is $NaN, with a low estimate of $NaN and a high estimate of $NaN. This represents a NaN% decrease compared to PEPG previous annual EPS of $NaN (undefined).
PepGen Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| IPSC | Century Therapeutics | $1.26 | $20.00 | 1487.30% | Buy |
| PMVP | PMV Pharmaceuticals | $1.64 | $24.75 | 1409.15% | Buy |
| ANTX | AN2 Therapeutics | $1.08 | $8.75 | 710.19% | Buy |
| MOLN | Molecular Partners | $6.06 | $29.00 | 378.55% | Buy |
| PEPG | PepGen | $6.79 | $29.50 | 334.46% | Buy |
| CMPX | Compass Therapeutics | $1.70 | $5.00 | 194.12% | Buy |
| VIGL | Vigil Neuroscience | $3.87 | $11.00 | 184.24% | Buy |
| PRTC | PureTech Health | $20.83 | $57.00 | 173.64% | Buy |
| ELYM | Eliem Therapeutics | $5.11 | $13.00 | 154.40% | Buy |
| MLYS | Mineralys Therapeutics | $13.50 | $30.00 | 122.22% | Buy |
| CCCC | C4 Therapeutics | $6.45 | $13.50 | 109.30% | Buy |
| CGEM | Cullinan Oncology | $15.92 | $31.50 | 97.86% | Buy |
| TYRA | Tyra Biosciences | $16.42 | $30.50 | 85.75% | Buy |
| PHVS | Pharvaris | $23.93 | $39.67 | 65.78% | Buy |
| EWTX | Edgewise Therapeutics | $34.48 | $45.00 | 30.51% | Buy |
| TRDA | Entrada Therapeutics | $17.77 | $18.00 | 1.29% | Buy |
PEPG Forecast FAQ
Is PepGen a good buy?
Yes, according to 2 Wall Street analysts, PepGen (PEPG) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 2 'Buy' recommendations, accounting for 100.00% of PEPG's total ratings.
What is PEPG's price target?
PepGen (PEPG) average price target is $29.5 with a range of $26 to $33, implying a 334.46% from its last price of $6.79. The data is based on 2 Wall Street analysts who provided a twelve-month price target estimate in the last three months.
Will PepGen stock go up soon?
According to Wall Street analysts' prediction for PEPG stock, the company can go up by 334.46% (from the last price of $6.79 to the average price target of $29.5), up by 386.01% based on the highest stock price target, and up by 282.92% based on the lowest stock price target.
Can PepGen stock reach $10?
PEPG's average twelve months analyst stock price target of $29.5 supports the claim that PepGen can reach $10 in the near future.
What are PepGen's analysts' financial forecasts?
PepGen's analysts financial forecasts for the fiscal year (Dec 2024) are as follows: average revenue is $0 (high $0, low $0), average EBITDA is $0 (high $0, low $0), average net income is $-79.63M (high $-72.175M, low $-83.195M), average SG&A $0 (high $0, low $0), and average EPS is $-2.452 (high $-2.223, low $-2.562). PEPG's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $0 (high $0, low $0), average EBITDA is $0 (high $0, low $0), average net income is $-108M (high $-108M, low $-108M), average SG&A $0 (high $0, low $0), and average EPS is $-3.328 (high $-3.328, low $-3.328).